Newsletter - June 25, 2020
Gottlieb and McClellan Critique FDA’s Requirements for COVID Clinical Trials
In a rare criticism of FDA’s requirements for clinical trials, two former commissioners of FDA, Scott Gottlieb and Mark McClellan, argue that FDA should allow practical trial designs of the kind used to evaluate dexamethasone treatment in COVID patients in the UK where data collection was “limited to most important measures...Read More
Stem cell clinics should file an IND, Now
Stem cell clinics should file INDs immediately, patients looking for stem cell treatments should only do so for those offered under INDs, patients should ask for informed consent, not pay for the treatment, and report adverse events. Or so FDA would want to see. In an article last week in the Journal of American Medical Association...Read More
Gottlieb and McClellan Critique FDA’s Requirements for COVID Clinical Trials
In a rare criticism of FDA’s requirements for clinical trials, two former commissioners of FDA, Scott Gottlieb and Mark McClellan, argue that FDA should allow practical trial designs of the kind used to evaluate dexamethasone treatment in COVID patients in the UK where data collection was “limited to most important measures...Read More
Stem cell clinics should file an IND, Now
Stem cell clinics should file INDs immediately, patients looking for stem cell treatments should only do so for those offered under INDs, patients should ask for informed consent, not pay for the treatment, and report adverse events. Or so FDA would want to see. In an article last week in the Journal of American Medical Association...Read More
